Stock Analiz

InspireMD, Inc. NSPR

Medical/Dental Instruments · data as of November 13, 2026

$0.64Market cap $30M
Open the interactive analysis →

InspireMD, Inc. (NSPR) is a healthcare company listed in the US with a market value of about $30M. In the twelve months to September 30, 2026 it had revenue of $11M and net income of -$40M, a net margin of -376.6%.

Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 29% a year, a 5-year average ROIC of -57%.

About InspireMD

InspireMD is listed in the US and classified in medical/dental instruments. Revenue went from $3M in 2014 to $9M in 2025, growth of about 11.1% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 717% over three years (dilution for shareholders). It spends 167% of revenue on research and development.

Score: 1.2 / 5

Value0/5
Future growth3/5
Track record1/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S2.9
P/B1.0
EV/EBITDA0.0
PEG—
Dividend yield0.00%
FCF yield-122.0%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)28.1%
Revenue growth (5 yrs, per year)29.3%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-402.1%
ROIC (5-yr avg.)-57.4%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$11M$9M$7M$6M$5M$4M$2M$4M$4M$3M$2M
Net income-$40M-$49M-$32M-$20M-$18M-$15M-$11M-$10M-$7M-$8M-$8M
Free cash flow—-$37M-$23M-$17M-$16M-$14M-$9M-$10M-$8M-$8M-$8M
EPS (diluted)$-0.49$-0.76$-0.76$-0.82$-2.35$-2.03$-6.97$-72.00$-250.05$-26235.00$-155789.99
Net margin-376.6%-543.3%-456.6%-321.0%-357.6%-331.9%-424.3%-269.8%-201.1%-305.6%-446.7%
ROIC—-67.0%-68.9%-39.9%-77.8%-33.5%-62.3%-128.5%-68.6%-238.5%-89.8%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 3 analysts is $3.33, 418% above the current price; targets range from $3.00 to $4.00; the consensus rating is “Buy”; expected EPS is $-0.44 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does InspireMD pay a dividend?

Not currently.

Is InspireMD a good stock to buy?

We do not give buy or sell advice. InspireMD scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.